COMPASS THERAP. DL-,0001 Aktie Logo
US20454B1044
A2QF3P
CMPX

COMPASS THERAP. DL-,0001 Aktie

Loading quotes...

Forecast

The analysts' average price target is €4.25 (+608.33%). The median is €3.64 (+506.67%).

Buy
  16
Hold
  1
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Compass Therapeutics reports positive phase 1 data for CTX-8371, stock remains under pressure

    Compass Therapeutics released phase 1 data on CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, showing three responses among 15 evaluable patients, including a >90% reduction in a case of triple-negative breast cancer. In the two highest dose cohorts (3.0 and 10.0 mg/kg) the overall response rate was 33% (2 of 6). No dose-limiting toxicities were observed; adverse events were mostly grade 1–2, with one asymptomatic grade 3 lipase elevation. The company has expanded cohorts for NSCLC, triple-negative breast cancer and Hodgkin lymphoma; additional data are expected in Q4 2026 and the results will be presented on May 30, 2026 at ASCO. Despite the clinical progress, the stock remains under pressure (market cap $326m, YTD loss 65% near a 52-week low) and investors are concerned about rapid cash burn. » More on de.investing.com


  • Compass Therapeutics stock falls 80% after mixed COMPANION-002 data and approval concerns

    Compass Therapeutics’ shares plunged 80% after the Phase II/III COMPANION-002 study of tovecimig plus paclitaxel in cholangiocarcinoma produced mixed results. Progression-free survival showed high statistical significance, but the overall survival endpoint was not met. The company and analysts say the OS result was affected by frequent crossover of control patients into the tovecimig arm (54%), raising questions about the dataset’s suitability for FDA approval. A pre-BLA meeting in mid‑2026 is expected as the next key milestone, and investors anticipate continued volatility. » More on de.investing.com


  • Compass Therapeutics: Tovecimig plus Paclitaxel meets secondary PFS endpoint in cholangiocarcinoma

    Compass Therapeutics reports that the combination of Tovecimig and Paclitaxel in the COMPANION-002 study met the secondary endpoint of progression-free survival (median PFS 4.7 vs. 2.6 months) with a hazard ratio of 0.44. The primary endpoint ORR was previously significant at 17.1% vs. 5.3%; overall survival did not reach significance, influenced by a 54% crossover in the control arm. Common adverse events included hypertension, fatigue and neutropenia; Compass plans a meeting with the FDA before a planned regulatory submission and will present the full data at a conference. » More on de.investing.com


  • Compass Therapeutics rises after Craig‑Hallum buy recommendation

    Compass Therapeutics shares rose 3.1% after Craig‑Hallum initiated coverage with a buy rating and a $15.00 price target. The research firm praised the company’s BsAb approach and highlighted Tovecimig (PD‑1xVEGF‑A) as a potential second‑line agent for cholangiocarcinoma. Craig‑Hallum also pointed to promising early‑phase candidates such as CTX‑8371 and CTX‑10726 and sees further upside over the next 12–18 months as the company transitions to the commercial phase. » More on de.investing.com


  • Compass Therapeutics reaches 52-week high at $5.86

    Shares of Compass Therapeutics climbed to a new 52-week high of $5.86 and are currently trading at $5.78. Over the past year the stock rose 249.4%, and year-to-date by about 300%, lifting the market capitalization to roughly $1.03 billion. The biotech is not yet profitable but shows strong liquidity with a current ratio of 17.82; analyst price targets range from $8 to $30, while the RSI points to a possible overbought condition. Compass plans to present preclinical data on its bispecific antibody candidate CTX-10726 at the annual meeting of the Society for Immunotherapy of Cancer, which is seen as a significant development step. » More on de.investing.com

Financials

In the last quarter, COMPASS THERAP. DL-,0001 Aktie had revenue of €0 and net profit of -€23.99M
(EUR) September 2026
YoY
Revenue 0 -
Gross profit 0 -
Net profit -23.99M 97.42%
EBITDA -23.65M 99.80%

Fundamentals

Metric Value
Market capitalization
€126.77M
Number of shares
180.09M
52-week high/low
€6.26 - €0.61
Dividends No
Beta
0.91
P/E ratio
-1.66
PEG ratio
68.63
P/B ratio
1.01
P/S ratio
0.00

Company profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Name
COMPASS THERAP. DL-,0001 Aktie
CEO
Thomas J. Schuetz
Headquarters Boston, ma
USA
Website
Industry
Food Products
IPO
04/05/2021
Employees 39

Ticker symbols

Exchange Symbol
NASDAQ
CMPX
🍪

Parqet  uses cookies. Learn more